Alkali therapy for metabolic acidosis in CKD G4 with borderline hyperkalemia

CKD Managementmedium

A 65-year-old man with CKD stage 4 is seen in the nephrology clinic for routine follow-up. His past medical history includes hypertension and coronary artery disease treated with percutaneous transluminal coronary angioplasty and stenting over 10 years ago. His medications include losartan, aspirin, metoprolol, furosemide, and simvastatin. His BP is 128/70 mm Hg, and his physical examination is unremarkable. Laboratory data: potassium 5.1 mEq/L (reference 3.5–5.0); total CO₂ 17 mEq/L (23–28); creatinine 2.7 mg/dL (baseline) (0.7–1.3); eGFR 25 mL/min/1.73 m² (≥60); calcium 9.2 mg/dL (8.6–10.2); phosphorus 4.7 mg/dL (3.0–4.5). Urine albumin-to-creatinine ratio is <30 mg/g (reference range, <30). Which ONE of the following is the BEST next step in management of this patient's electrolyte abnormalities?

  1. A.Potassium citrate PO
  2. B.Reduce animal protein intake to <0.5 g/kg/day
  3. C.Monitor serum electrolytes every 3 months
  4. D.Sodium bicarbonate POCorrect

Explanation

This patient with advanced CKD and worsening metabolic acidosis should be prescribed sodium bicarbonate PO. Chronic metabolic acidosis is a common complication of advanced CKD and has been associated with increased mortality, muscle wasting, bone disease, and CKD progression. KDIGO guidelines recommend bicarbonate supplementation in patients with a serum total CO₂ <22 mEq/L. Supplementation can be done in the form of sodium bicarbonate or sodium citrate, with dosing of 0.5–1 mEq/kg/day. Although studies have shown that the addition of base-containing foods such as fruits and vegetables can ameliorate metabolic acidosis in patients with CKD, KDIGO guidelines advise caution in using this approach in patients with hyperkalemia. Because the treatment of metabolic acidosis has been shown to slow the rate of progression of CKD, simply monitoring electrolytes in the presence of worsening acidosis would not be an appropriate management strategy. A reduction of animal protein intake may be helpful in reducing the dietary acid load but would likely be insufficient to correct the serum bicarbonate level. Additionally, decreased protein intake by itself would risk nutritional deficiency, although substitution with vegetable sources of protein may be recommended. Potassium citrate is a form of alkali that is often used to treat renal tubular acidoses. However, the use of potassium citrate to correct acidosis in patients with CKD is not recommended due to the potential risk of hyperkalemia in patients with diminished ability to renally excrete potassium.

Why each option

A.
Potassium citrate supplies alkali but adds a potassium load in a patient with eGFR 25 and potassium already 5.1 mEq/L.
B.
Protein restriction below 0.5 g/kg/day risks malnutrition and alone is insufficient to correct a bicarbonate of 17 mEq/L.
C.
Monitoring alone leaves a bicarbonate of 17 mEq/L untreated despite its association with muscle wasting, bone disease, and CKD progression.
D.
Correct. Total CO₂ of 17 mEq/L in CKD G4 warrants oral sodium bicarbonate, which avoids a potassium load in a patient with potassium 5.1 mEq/L.

Reference: KDIGO 2024 Clinical Practice Guideline for CKD; de Brito-Ashurst I, J Am Soc Nephrol 2009 (bicarbonate supplementation slows CKD progression)

This is one of 1,100 questions in the MedBoardSA nephrology bank, with timed test mode, tutor mode, and progress tracking by topic.

Practise the full bank

More CKD Management questions

Browse other topics